Johnson & Johnson

News

GSK licenses hepatitis B drug from J&J in $1bn deal

GSK has set its sights on dominance of the market for hepatitis B virus (HBV) therapeutics, licensing an antisense oligonucleotide drug from Arrowhead Pharma and Johnson &

News

Lilly finally gets FDA OK for ulcerative colitis drug Omvoh

After an earlier rejection, the FDA has approved Eli Lilly’s first-in-class IL-23p19 inhibitor mirikizumab as a treatment for adults with moderately to severely active ulc

News

China clears ViiV, J&J injectable HIV treatment

ViiV Healthcare and Johnson & Johnson have been granted approval in China for a long-acting HIV therapy that frees patients from the need to take daily pills to keep t

News

ESMO: J&J’s Tagrisso challenge, and other highlights

With Europe’s premier cancer congress ESMO now finished, we close our coverage with a look at some other important new studies that generated a buzz at the show.

News

AZ’s Tagrisso plus chemo get fast FDA review for lung cancer

AstraZeneca will hear back from the FDA in the first quarter of next year about its recent filing of Tagrisso in combination with chemotherapy as a first-line treatment fo

News

AbbVie’s Skyrizi bests Stelara in Crohn’s contest

AbbVie has built the case for its IL-23 inhibitor Skyrizi as a treatment for Crohn’s disease, saying its drug was more effective than Johnson & Johnson’s widely-used S

GSK licenses hepatitis B drug from J&J in $1bn deal

Lilly finally gets FDA OK for ulcerative colitis drug Omvoh

China clears ViiV, J&J injectable HIV treatment

ESMO: J&J’s Tagrisso challenge, and other highlights

AZ’s Tagrisso plus chemo get fast FDA review for lung cancer

AbbVie’s Skyrizi bests Stelara in Crohn’s contest

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

Johnson & Johnson

Editor's Picks